Abstract:
In 2025, the Korean Society of Neurogastroenterology and Motility published the 2025 Seoul Consensus on Clinical Practice Guidelines for Irritable Bowel Syndrome. Using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) framework to rate the quality of evidence and strength of recommendations, the consensus developed 22 recommendations covering the definition and subtypes, diagnostic strategies, lifestyle interventions, pharmacological treatment, and psychological therapies for irritable bowel syndrome (IBS). Its principal recommendations include:adopting a positive diagnostic strategy for IBS; implementing lifestyle interventions, including a diet low in fermentable oligosaccharides, disaccharides, monosaccharides and polyols (FODMAPs), as well as appropriate physical activity; refining pharmacological treatment options for IBS with predominant constipation and IBS with predominant diarrhea, particularly the use of secretagogues, serotonin type 3 receptor antagonists, serotonin type 4 receptor agonists, rifaximin, and neuromodulators; and incorporating gut-directed psychological therapies into the management of refractory IBS. This article interprets these recommendations and compares them with authoritative Chinese and international consensuses and guidelines, aiming to inform the precise diagnosis, individualized treatment, and long-term management of IBS in China. Notably, most evidence underpinning the consensus was derived from Korean, European, and North American populations, with limited support from high-quality clinical studies conducted in China. The applicability of these recommendations to Chinese patients therefore requires further validation. In clinical practice, the recommendations should be applied prudently in consideration of the characteristics of Chinese patients and locally generated evidence.